Increased expression and genomic organization of a folate-binding protein homologous to the human placental isoform in L1210 murine leukemia cell lines with a defective reduced folate carrier

Kevin E. Brigle, Richard Seither, Eric H. Westin, I. David Goldman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport. In this line, the reduced folate carrier had unchanged affinity for methotrexate, was present at the cell surface in usual quantity, but did not deliver drug into the cell, indicative of a functional defect in the translocation process. In this study, we further characterize this cell line along with a subline (F2-MTX(r)A) selected for growth in low levels of folic acid. This subline demonstrates continued high resistance to methotrexate and very low influx of [3H]methotrexate and 5-[3H]formyltetrahydrofolate, indicating the persistence of the defect in the reduced folate carrier. Both MTX(r)A and F2-MTX(r)A are shown to overexpresses FBP2, the murine homolog of a folate-binding protein initially isolated from human placenta. Compared with parent L1210 cells, Northern analysis revealed FBP2 expression to be elevated 40-fold in the MTX(r)A line and 500-fold in F2-MTX(r)A. The large increase in FBP2 expression in the F2-MTX(r)A line correlates with a 10-fold increase in [3H]folic acid membrane surface binding and a 1000-fold decrease in the folic acid growth requirement compared with parental L1210 cells. Also, there are 20- and 500-fold decreases in the 5-formyltetrahydrofolate growth requirement compared with parent L1210 and MTX(r)A cells, respectively. Finally, the genomic organization of the FBP2 locus is presented. The results of Northern analyses using probes specific to FBP2 5'- untranslated sequences or to a splice junction within this region suggest that the up-regulated FBP2-specific message in F2-MTX(r)A utilizes 5'- noncoding sequences distinct from those used in the message encoded in L1210 cell lines with low level FBP2 expression. The MTX(r)A cells provide an example of a line selected for primary resistance to methotrexate that also exhibits concomitant increased expression of a folate-binding protein. Further overexpression of this folate-binding protein (which has homology to that initially identified in placenta) provides cells with the ability to meet cellular folate needs in a folate-deprived environment.

Original languageEnglish (US)
Pages (from-to)4267-4272
Number of pages6
JournalJournal of Biological Chemistry
Volume269
Issue number6
StatePublished - Feb 11 1994
Externally publishedYes

Fingerprint

Reduced Folate Carrier Protein
Leukemia L1210
Folic Acid
Carrier Proteins
Protein Isoforms
Cells
Cell Line
Methotrexate
Leucovorin
Placenta
Formyltetrahydrofolates
Growth
Defects
Membranes

ASJC Scopus subject areas

  • Biochemistry

Cite this

@article{f58a0e6945b14cadad036bb485a53105,
title = "Increased expression and genomic organization of a folate-binding protein homologous to the human placental isoform in L1210 murine leukemia cell lines with a defective reduced folate carrier",
abstract = "This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport. In this line, the reduced folate carrier had unchanged affinity for methotrexate, was present at the cell surface in usual quantity, but did not deliver drug into the cell, indicative of a functional defect in the translocation process. In this study, we further characterize this cell line along with a subline (F2-MTX(r)A) selected for growth in low levels of folic acid. This subline demonstrates continued high resistance to methotrexate and very low influx of [3H]methotrexate and 5-[3H]formyltetrahydrofolate, indicating the persistence of the defect in the reduced folate carrier. Both MTX(r)A and F2-MTX(r)A are shown to overexpresses FBP2, the murine homolog of a folate-binding protein initially isolated from human placenta. Compared with parent L1210 cells, Northern analysis revealed FBP2 expression to be elevated 40-fold in the MTX(r)A line and 500-fold in F2-MTX(r)A. The large increase in FBP2 expression in the F2-MTX(r)A line correlates with a 10-fold increase in [3H]folic acid membrane surface binding and a 1000-fold decrease in the folic acid growth requirement compared with parental L1210 cells. Also, there are 20- and 500-fold decreases in the 5-formyltetrahydrofolate growth requirement compared with parent L1210 and MTX(r)A cells, respectively. Finally, the genomic organization of the FBP2 locus is presented. The results of Northern analyses using probes specific to FBP2 5'- untranslated sequences or to a splice junction within this region suggest that the up-regulated FBP2-specific message in F2-MTX(r)A utilizes 5'- noncoding sequences distinct from those used in the message encoded in L1210 cell lines with low level FBP2 expression. The MTX(r)A cells provide an example of a line selected for primary resistance to methotrexate that also exhibits concomitant increased expression of a folate-binding protein. Further overexpression of this folate-binding protein (which has homology to that initially identified in placenta) provides cells with the ability to meet cellular folate needs in a folate-deprived environment.",
author = "Brigle, {Kevin E.} and Richard Seither and Westin, {Eric H.} and Goldman, {I. David}",
year = "1994",
month = "2",
day = "11",
language = "English (US)",
volume = "269",
pages = "4267--4272",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "6",

}

TY - JOUR

T1 - Increased expression and genomic organization of a folate-binding protein homologous to the human placental isoform in L1210 murine leukemia cell lines with a defective reduced folate carrier

AU - Brigle, Kevin E.

AU - Seither, Richard

AU - Westin, Eric H.

AU - Goldman, I. David

PY - 1994/2/11

Y1 - 1994/2/11

N2 - This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport. In this line, the reduced folate carrier had unchanged affinity for methotrexate, was present at the cell surface in usual quantity, but did not deliver drug into the cell, indicative of a functional defect in the translocation process. In this study, we further characterize this cell line along with a subline (F2-MTX(r)A) selected for growth in low levels of folic acid. This subline demonstrates continued high resistance to methotrexate and very low influx of [3H]methotrexate and 5-[3H]formyltetrahydrofolate, indicating the persistence of the defect in the reduced folate carrier. Both MTX(r)A and F2-MTX(r)A are shown to overexpresses FBP2, the murine homolog of a folate-binding protein initially isolated from human placenta. Compared with parent L1210 cells, Northern analysis revealed FBP2 expression to be elevated 40-fold in the MTX(r)A line and 500-fold in F2-MTX(r)A. The large increase in FBP2 expression in the F2-MTX(r)A line correlates with a 10-fold increase in [3H]folic acid membrane surface binding and a 1000-fold decrease in the folic acid growth requirement compared with parental L1210 cells. Also, there are 20- and 500-fold decreases in the 5-formyltetrahydrofolate growth requirement compared with parent L1210 and MTX(r)A cells, respectively. Finally, the genomic organization of the FBP2 locus is presented. The results of Northern analyses using probes specific to FBP2 5'- untranslated sequences or to a splice junction within this region suggest that the up-regulated FBP2-specific message in F2-MTX(r)A utilizes 5'- noncoding sequences distinct from those used in the message encoded in L1210 cell lines with low level FBP2 expression. The MTX(r)A cells provide an example of a line selected for primary resistance to methotrexate that also exhibits concomitant increased expression of a folate-binding protein. Further overexpression of this folate-binding protein (which has homology to that initially identified in placenta) provides cells with the ability to meet cellular folate needs in a folate-deprived environment.

AB - This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport. In this line, the reduced folate carrier had unchanged affinity for methotrexate, was present at the cell surface in usual quantity, but did not deliver drug into the cell, indicative of a functional defect in the translocation process. In this study, we further characterize this cell line along with a subline (F2-MTX(r)A) selected for growth in low levels of folic acid. This subline demonstrates continued high resistance to methotrexate and very low influx of [3H]methotrexate and 5-[3H]formyltetrahydrofolate, indicating the persistence of the defect in the reduced folate carrier. Both MTX(r)A and F2-MTX(r)A are shown to overexpresses FBP2, the murine homolog of a folate-binding protein initially isolated from human placenta. Compared with parent L1210 cells, Northern analysis revealed FBP2 expression to be elevated 40-fold in the MTX(r)A line and 500-fold in F2-MTX(r)A. The large increase in FBP2 expression in the F2-MTX(r)A line correlates with a 10-fold increase in [3H]folic acid membrane surface binding and a 1000-fold decrease in the folic acid growth requirement compared with parental L1210 cells. Also, there are 20- and 500-fold decreases in the 5-formyltetrahydrofolate growth requirement compared with parent L1210 and MTX(r)A cells, respectively. Finally, the genomic organization of the FBP2 locus is presented. The results of Northern analyses using probes specific to FBP2 5'- untranslated sequences or to a splice junction within this region suggest that the up-regulated FBP2-specific message in F2-MTX(r)A utilizes 5'- noncoding sequences distinct from those used in the message encoded in L1210 cell lines with low level FBP2 expression. The MTX(r)A cells provide an example of a line selected for primary resistance to methotrexate that also exhibits concomitant increased expression of a folate-binding protein. Further overexpression of this folate-binding protein (which has homology to that initially identified in placenta) provides cells with the ability to meet cellular folate needs in a folate-deprived environment.

UR - http://www.scopus.com/inward/record.url?scp=0028111514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028111514&partnerID=8YFLogxK

M3 - Article

C2 - 8307991

AN - SCOPUS:0028111514

VL - 269

SP - 4267

EP - 4272

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 6

ER -